Author: Ravi Shankar

First well to test stacked Devonian and Cambrian Helium reservoir targets at Aden 

New REV Video: Why Helium Matters
https://youtu.be/V8IOCW8YyBo

KELOWNA, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) — REV Exploration Corp. (“REV” or the “Company”) (TSXV: REVX; OTCID: REVFF; FSE: 7FF) is pleased to announce that drilling has commenced at the Company’s 100%-owned Aden Dome Project along the Alberta-Montana border, marking the launch of a planned multi-well drill program targeting potential new Helium discoveries in the Northern Great Plains with a major focus on Montana.

Highlights

• Aden Dome’s combination of deep structural architecture, potential migration pathways, stacked porous reservoir intervals and structural closure forms the basis of REV’s discovery model for this advanced prospect located along a known Helium fairway;
• Drilling at Aden will test stacked Devonian Beaverhill Lake carbonates and the deeper Basal Cambrian sandstone within a seismically defined four-way structural closure;
• The deeper Basal Cambrian and Precambrian basement complex also offer Natural Hydrogen potential beyond the primary Helium objectives.

Mr. Jordan Potts, REV CEO, commented: “The drill bit is now turning, and a new chapter for REV is officially underway. Everything our team has been building, from our land packages to a series of compelling priority drill targets, has positioned REV as a leading Helium-focused opportunity serving America’s Northern Great Plains and southernmost Alberta. From Aden, we’ll move 20 miles southwest to our 6,171-acre West Butte Project where we have started the process of permitting multiple wells with the Montana Board of Oil and Gas Conservation.”

Drilling at Aden 12-4-1-9W4 is being carried out by Savanna Drilling Rig #416, a Super Single that just completed Lawson 2, Lawson 3, and Lawson 4 in south-central Saskatchewan for MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF). REV is in a technical collaboration with MAX Power and continues to own 6 million shares of the company.

Figure 1: Savanna Drill Rig #416 at Aden Dome

About REV Exploration Corp.

REV is a mineral exploration company with a diversified portfolio of strategic mining assets, together with meaningful and growing exposure to the Helium and Natural Hydrogen sectors focused on America’s Northern Great Plains and southernmost Alberta along the Montana border. The Company owns oil and gas leasehold interests in Montana covering approximately 10,600 acres, in addition to a series of PNG leases in Alberta along the Alberta–Montana border, including the Aden Dome Project. REV also owns 6 million shares of MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF) and 12.4 million shares of Major Gold Corp., a private company that is pursuing a listing on the TSX Venture Exchange.

For further information on the Company, readers are referred to the Company’s website at REVexploration.com and its Canadian regulatory filings on SEDAR+ at sedarplus.ca.

REV Exploration Corp.
Unit 220 – 1060 Manhattan Dr.
Kelowna, BC V1Y 9X9
Tel: 604-682-7970
info@revexploration.com
REVexploration.com

Jordan Potts, CEO and Director

For further information, please contact:
Chad Levesque
Investor Relations
1-306-981-4753
info@revexploration.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking information”). Forward-looking information in this release includes, but is not limited to, statements regarding the drilling of the Aden Well, including its planned total depth, target intervals and formation evaluation program; the timing of laboratory analysis and the reporting of results; the permitting and drilling of wells at West Butte; the advancement, prioritization and evaluation of exploration prospects; the geological potential of the Company’s properties, including for Helium and Natural Hydrogen; the proposed listing of Major Gold Corp. on the TSX Venture Exchange; and the Company’s future business strategy and objectives.

Forward-looking information is based on management’s expectations and reasonable assumptions as of the date of this news release, including, without limitation, assumptions regarding the availability of drilling equipment, technical personnel and service providers; operating and weather conditions; the accuracy and reliability of geological, geophysical and other technical information; the Company’s ability to obtain required permits and financing on reasonable terms if required; and general economic, market and business conditions.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, without limitation, risks relating to mineral and natural gas exploration and development, including the risk that exploration or drilling results may not confirm geological interpretations or expectations; risks inherent in drilling operations, including mechanical failure, hole instability, cost overruns, delays and accidents; the risk that the Aden Well may not reach its planned total depth or may not encounter reservoir, Helium or Natural Hydrogen in any target interval; the risk that gas indications may not be confirmed by laboratory analysis or testing; the speculative nature of early-stage exploration properties; permitting, land tenure, environmental compliance, regulatory and community relations risks; commodity price volatility; fluctuations in currency exchange rates; access to capital; dilution; reliance on key personnel, third-party consultants and contractors; and general economic, market, political and social uncertainties. Investors should review the risk factors and other disclosure contained in the Company’s public filings available under its profile on SEDAR+.

There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this news release, and the Company does not undertake any obligation to update or revise such information except as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f1303e3-7266-4b74-a6f6-f92b9db8d81f

BRENTWOOD, Tenn., Sept. 25, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic” or the “Company”) announced today that the Board of Directors of the Company has appointed Lucibeth N. Mayberry as President and Chief Executive Officer of the Company. Patrick D. Swindle has resigned as President and Chief Executive Officer due to health reasons. Mr. Swindle has served as President and Chief Executive Officer since January 1, 2026, following his appointment as President and Chief Operating Officer on January 1, 2025. In addition, Mr. Swindle resigned from CoreCivic’s Board, and Ms. Mayberry has been appointed to fill the vacancy.

Mr. Swindle said, “It is with a heavy heart that I am announcing my decision to resign as President and CEO of CoreCivic, as I pursue treatment for stage four metastatic pancreatic cancer. It has been the greatest professional honor of my life to serve as President and CEO of this Company. We have an excellent leadership team at CoreCivic, and Lucibeth has been an indispensable member of our executive leadership team, with whom I’ve worked closely for nineteen years on many critical strategic matters for the Company, including the property sales we announced earlier this year. Lucibeth is one of the most capable and principled leaders I know, and I have no doubt that under her stewardship, this Company will continue to grow and make a difference in the lives of the individuals entrusted to our care.”

Ms. Mayberry said, “Patrick is not only a remarkable leader but a valued colleague and a dear friend. I am personally thankful for his mentorship and his numerous contributions to CoreCivic, not just as Chief Executive Officer, but over the course of his many years with the Company. Patrick has been instrumental in leading CoreCivic through a significant period of development and change during his time as President and CEO. I am fully committed to continuing the current capital allocation strategy, maintaining our focus on operational excellence, and look forward to building on the progress already underway.”

Mark Emkes, chair of the Board of Directors, commented, “On behalf of the Board of Directors, I thank Patrick and extend our very best wishes to him and his family. Patrick helped make the Company stronger and more flexible and positioned the Company well for the future. We are profoundly grateful for everything Patrick has given to this organization, and we are honored that he will continue to lend his guidance as a special advisor during this transition. In appointing Lucibeth, the Board is recognizing her significant leadership and the trust she has earned across the organization. She has a deep understanding of our business, a proven ability to execute strategic initiatives, and the full confidence of the Board to lead CoreCivic forward while continuing the strategy that has strengthened the Company and created value for shareholders.”

Ms. Mayberry has served as the Executive Vice President and Chief Strategy Officer since May 2025. From October 2022 to May 2025, Ms. Mayberry served as the Executive Vice President and Chief Innovation Officer. Prior to assuming that role, Ms. Mayberry served as Executive Vice President, Real Estate from May 2015 until October 2022. She has previously served in various roles at CoreCivic since May 2003, including as Vice President, Deputy Chief Development Officer; Vice President, Research, Contract and Proposals; and as Managing Director, State Partnership Relations. Ms. Mayberry holds a bachelor’s degree from the University of Tennessee, a juris doctor from Vanderbilt University, and a Master of Laws degree in taxation from the University of Florida.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the transition of executive leadership at CoreCivic. These forward-looking statements may include such words as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. Important factors that could cause actual results to differ from our expectations are described in the filings made from time to time by CoreCivic with the Securities and Exchange Commission (“SEC”) and include the risk factors described in CoreCivic’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026 and subsequent filings.

CoreCivic takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services, except as may be required by law.

52053606.2

Contact:

Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024 Media: Steve Owen – Vice President, Communications – (615) 263-3107

LONDON, Sept. 25, 2026 (GLOBE NEWSWIRE) — Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”), a leading provider of Sustainability RegTech solutions, today announced that its Board of Directors has resolved to convene an Extraordinary General Meeting of shareholders (the “EGM”) to be held on Thursday, October 8, 2026 at 10:00 a.m. (Eastern Time), virtually via webcast and teleconference, for shareholders of record as of the close of business on August 14, 2026. On September 24, 2026, the notice of EGM, proxy statement and proxy card were furnished to the U.S. Securities and Exchange Commission (the “SEC”) under cover of Form 6-K.

At the EGM, the Company will seek shareholder approval of the following proposals:

Proposal 1. Transaction and Consideration Shares Proposal (the “Transaction Proposal”) – a proposal to resolve, by ordinary resolution, that:

(a) the Company’s entry into the Amended and Restated Sale and Purchase Agreement dated August 14, 2026 (the “A&R SPA”) among the Company and the sellers named therein, pursuant to which the Company has agreed to acquire the entire issued and outstanding share capital of Resulticks Global Companies Pte. Limited (“Resulticks”), together with the transactions contemplated thereby (collectively, the “Transaction”), be and hereby is authorized, approved and ratified in all respects;

(b) the acquisition by the Company of all of the issued and outstanding share capital of Resulticks pursuant to the A&R SPA, be and hereby is authorized, approved and ratified in all respects;

(c) subject to the Changes of Authorized Share Capital (as defined below), the allotment and issuance by the Company to the sellers under the A&R SPA of an aggregate of 600,000,000 ordinary shares of the Company, subject to such proportionate adjustment as may be required pursuant to the A&R SPA as a result of any consolidation, subdivision or other reorganization of the Company’s share capital (the “Consideration Shares”), credited as fully paid, be and hereby is authorized and approved; and

(d) the Directors of the Company (the “Directors”), or any one or more of them, be and hereby are authorized to take any and all actions and to execute, deliver and perform any and all agreements, certificates, instruments and other documents that they consider necessary, advisable or desirable to consummate the Transaction and give effect to this Transaction Proposal, including agreeing to such non-material amendments to the A&R SPA and related transaction documents as they may consider appropriate.

Proposal No. 2. Change of Control (the “Change of Control Proposal”) – a proposal, to resolve, by ordinary resolution, that the change of control of the Company resulting from the Transaction and the issuance of the Consideration Shares and other securities to be issued in connection therewith, including, to the extent applicable, for purposes of Nasdaq Listing Rule 5635(b), be and hereby is authorized and approved provided that nothing in this proposal shall constitute a waiver of or election not to rely upon any foreign-private-issuer home-country practice available to the Company under Nasdaq Listing Rule 5615(a)(3).

Proposal No. 3. Changes of Authorized Share Capital (the “Changes of Authorized Share Capital Proposal”) – a proposal, to resolve by ordinary resolution that, subject to and conditional upon the closing of the Transaction (other than the issuance of the Consideration Shares), the authorized share capital of the Company be increased and changed from US$200,000 divided into 495,000,000 ordinary shares of a par value of US$0.0004 each and 5,000,000 preferred shares of a par value of US$0.0004 each to US$520,000 divided into 1,300,000,000 ordinary shares of a par value of US$0.0004 each, by (i) the creation of 800,000,000 additional authorized ordinary shares of a par value of US$0.0004 each and (ii) the redesignation of 5,000,000 authorized but unissued preferred shares of US$0.0004 each as 5,000,000 authorized but unissued ordinary shares of a par value of US$0.0004 each (the “Changes of Authorized Share Capital”), each ranking pari passu in all respects with the existing shares of the same class.

Proposal No. 4. Share Consolidation (the “Share Consolidation Proposal”) – a proposal to resolve, by ordinary resolution that, immediately after the Changes of Authorized Share Capital takes effect, and subject to compliance with applicable law and the requirements of The Nasdaq Stock Market LLC:

(a) every ten (10) then issued and unissued ordinary shares of the Company of a par value of US$0.0004 each be consolidated into one (1) ordinary share of a par value of US$0.004 each (each, a “Consolidated Ordinary Share”), with such Consolidated Ordinary Shares ranking pari passu in all respects with one another and having the same rights and being subject to the same restrictions as the existing ordinary shares as set out in the existing memorandum and articles of association of the Company, save as to par value (the “Share Consolidation”);

(b) no fractional Consolidated Ordinary Shares shall be issued and any fractional entitlement otherwise arising shall be rounded up to the next whole Consolidated Ordinary Share, such that the authorized share capital of the Company shall become US$520,000 divided into 130,000,000 ordinary shares of a par value of US$0.004 each; and 

(c) the number of ordinary shares, warrants, options, restricted share units, performance share units and other securities or rights exercisable for, convertible into or otherwise referencing ordinary shares of the Company, together with the applicable exercise, conversion or subscription prices thereof, shall be adjusted to reflect the Share Consolidation to the extent required by their terms and, in the case of securities issued or issuable pursuant to the A&R SPA, in accordance with the terms of the A&R SPA.

Proposal No. 5. Amended and Restated Memorandum and Articles of Association Proposal (the “M&AA Amendment Proposal”) – a proposal to resolve, by special resolution, that subject to the Changes of Authorized Share Capital and Share Consolidation taking effect, the third amended and restated memorandum and articles of association of the Company be and hereby are approved and adopted in their entirety, in substitution for and to the exclusion of the existing second amended and restated memorandum and articles of association of the Company and the Directors, be and hereby are authorized to take all actions and make all filings with the Registrar of Companies of the Cayman Islands and any other governmental or regulatory authority that they consider necessary, advisable or desirable.

Proposal No. 6. Equity Incentive Plan Proposal (the “EIP Proposal”) – a proposal to resolve, by ordinary resolution, that the second amended and restated 2024 Omnibus Incentive Plan of the Company be and hereby is approved and adopted in its entirety and in substitution for and to the exclusion of the existing Amended and Restated 2024 Omnibus Incentive Plan of the Company, such that (i) the aggregate number of shares that are available for issuance thereunder shall be increased from 5,400,000 ordinary shares to 9,000,000 ordinary shares (after factoring in the adjustment to be made as a result of the Share Consolidation), and (ii) all references to the par value of the ordinary shares of the Company shall be updated to reflect the revised par value as adjusted as a result of the Share Consolidation, and the Directors be and hereby are authorized to administer and implement such plan in accordance with its terms.

Proposal No. 7. Ancillary Transaction Agreements Proposal (the “Ancillary Agreements Proposal”) – a proposal to resolve, by ordinary resolution, that to the extent not previously validly issued or approved and subject to the terms described in the Notice of Extraordinary General Meeting and accompanying proxy statement, the following transactions be and hereby are approved and, where appropriate, ratified and confirmed: (a) the Amended and Restated Deed of Undertaking dated August 14, 2026, including the termination and cancellation of the Diginex Founder Warrants, Outstanding IPO Warrants and applicable restricted stock units and performance stock units issued to Miles Pelham and the allotment and issuance of up to 40,000,000 ordinary shares to Rhino Ventures Limited, subject to the forfeiture / treasury-share or alternative security arrangements contemplated by the Transaction documents; (b) the Resulticks Additional Investment (as defined in the A&R SPA), including up to approximately 58,823,530 ordinary shares; and (c) up to 15,000,000 ordinary shares payable to the transaction introducer, in each case subject to proportionate adjustment for the Share Consolidation; provided that nothing in this proposal shall constitute a waiver of or election not to rely upon any foreign-private-issuer home-country practice available to the Company under Nasdaq Listing Rule 5615(a)(3).

Proposal No. 8. Adjournment Proposal (the “Adjournment Proposal”) – a proposal to resolve, by ordinary resolution, that the chairman of the Extraordinary General Meeting be and hereby is authorized to adjourn the Meeting to a later date or dates, on one or more occasions, if necessary or advisable (a) to permit any required or advisable supplement or amendment to the Notice of Extraordinary General Meeting and accompanying proxy statement to be furnished to shareholders, (b) to permit the Company to solicit additional proxies in favor of any proposal submitted at the Meeting or (c) if the chairman otherwise determines that an adjournment is necessary or advisable to facilitate the orderly conduct of the Extraordinary General Meeting or completion of the Transaction.

Full details of the proposals to be presented to the Company’s shareholders are set out in the Notice of EGM and accompanying proxy statement and proxy card, which have been furnished to the SEC under cover of Form 6-K and are available at www.sec.gov, at https://www.cstproxy.com/diginex/egm2026 and on the Company’s website at www.diginex.com. These materials are expected to be mailed to shareholders on or about September 24, 2026. The Company’s Ordinary Shares will continue to trade on Nasdaq under the symbol “DGNX”. The Board of Directors has unanimously approved each of the proposals and recommends that shareholders vote “FOR” each of them. Shareholders are urged to read the proxy materials carefully and to vote their shares.

The EGM will be accessible by webcast at https://www.cstproxy.com/diginex/egm2026 and by listen-only teleconference on 1 800-450-7155 (toll-free within the U.S. and Canada) or +1 857-999-9155 (outside the U.S. and Canada; standard rates apply), Conference ID 0374507#. Shareholders may vote by internet at www.cstproxyvote.com or https://www.cstproxy.com/diginex/egm2026, or by returning a completed proxy card by mail, and may change their vote online until 11:59 p.m. (Eastern Time) on October 7, 2026. Shareholders holding through a broker, bank or other nominee should follow the instructions provided by their nominee. Shareholders who need assistance with voting may contact Continental Stock Transfer & Trust Company at proxy@continentalstock.com or (917) 262-2373.

The Company remains focused on executing its strategic priorities and advancing its long-term business objectives. 

About Diginex

Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”) is a London-headquartered RegTech business, providing ESG, sustainability and compliance solutions through an integrated platform trusted by global enterprises and financial institutions.

Its portfolio of products and services spans the full sustainability lifecycle, including Diginex ESG (reporting), Plan A (carbon accounting), Matter (data and investment intelligence), Lumen (supply chain risk and traceability), Apprise (worker voice), and The Remedy Project (human rights remediation), combining technology, analytics and advisory services to turn verified data into decision-ready business intelligence.

For more information, please visit the Company’s website: https://www.diginex.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These include, but are not limited to, statements regarding the timing and outcome of the EGM, the implementation and expected effects of the proposed share consolidation, the proposed acquisition of Resulticks and its expected timing, approval of the Company’s Nasdaq initial listing application in connection with the Transaction, and the Company’s strategic plans. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the SEC.

Diginex
Investor Relations
Email: ir@diginex.com

IR Contact – Europe
Jan Hutterer
Kirchhoff Consult
Phone: +49 (40) 609186-0
Email: diginex@kirchhoff.de

IR Contact – US
Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: jian.lin@llyc.global

TR-1: Standard form for notification of major holdings

1. Issuer Details
ISIN
GB0009067447
Issuer Name
MOTHERCARE PLC.
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Clive Whiley
City of registered office (if applicable)
Country of registered office (if applicable)
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached
25-Sep-2026
6. Date on which Issuer notified
25-Sep-2026
7. Total positions of person(s) subject to the notification obligation

.	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	11.3476	0.000000	11.3476	65000000
Position of previous notification (if applicable)	8.8678	0.000000	8.8678	50000000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009067447	65000000	0	11.3476	0.000000
Sub Total 8.A	65000000		11.3476%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting
Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion
25-Sep-2026
13. Place Of Completion
UK

Additional 10-Year Term adds ~$5.2 Billion of Contracted Revenue at Barber Lake

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a leading developer, owner, and operator of industrial-scale data centers, today announced a series of agreements that extend the contracted lease duration of its Barber Lake data center in Colorado City, Texas from 10 years to 20 years and increase total contracted revenue at the facility from $3.8 billion to over $9 billion.

Cipher has executed an amendment to its existing lease with Fluidstack (the “Barber Lake Lease”) that is coupled with a binding commitment with a leading AI lab to lease the facility for an additional 10-year term following the conclusion of the Barber Lake Lease. The additional 10-year commitment with the leading AI lab, which will be governed by a separate lease containing economic terms substantially consistent with the Barber Lake Lease, is expected to generate approximately $5.2 billion of incremental contracted revenue.

In connection with change orders and the continued evolution of tenant requirements at Barber Lake, the lease amendment establishes a phased delivery schedule for the site, with individual data halls expected to be delivered from the fourth quarter of 2026 through the first quarter of 2027. Rent will commence for each data hall as it is delivered, with the first rent commencement expected in the fourth quarter of 2026. Cipher remains on track with the revised delivery schedule.

In connection with the amendment and the change orders, the Company, Fluidstack and the leading AI lab established a cost reimbursement framework, pursuant to which the Company will bear the first $359.3 million of costs in excess of the initial budgeted amount under the Barber Lake Lease. The tenant will reimburse the Company over the aggregate twenty-year term for 50% of any such costs above that amount, payable as additional rent and calculated in a manner to provide Cipher with a contracted rate of return on such reimbursed amounts.

“Extending Barber Lake’s contracted life from 10 to 20 years and adding approximately $5.2 billion of contracted revenue reflects the enduring value of the infrastructure we’re building,” said Tyler Page, Chief Executive Officer. “Barber Lake was designed as a long-lived, mission-critical asset, and securing a firm commitment that extends well beyond the original lease term demonstrates the long-term utility and strategic relevance of the campus. We believe this transaction underscores the quality and enduring strength of our sites, as well as the durability of demand for hyperscale computing capacity.”

About Cipher

Cipher develops and operates industrial-scale data centers engineered for next-generation computing at the highest standards of innovation, precision, and excellence. The Company brings together deep expertise across power sourcing, construction, engineering, operations, real estate, and technology to deliver high-quality data centers purpose built for HPC workloads. By partnering with premier tenants, Cipher seeks to meet the growing demand for industrial-scale data center capacity and become a leading HPC development platform that is built for hyperscale. To learn more about Cipher, please visit https://www.cipherdigital.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws of the United States. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, such as statements about the Company’s beliefs and expectations regarding its planned business model and strategy, timing and likelihood of success, capacity, functionality and operation of its data centers, expectations regarding its data center development and operations, potential strategic initiatives, and management plans and objectives, are forward-looking statements and should be evaluated as such. These forward-looking statements generally are identified by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “seeks,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “strategy,” “future,” “forecasts,” “opportunity,” “predicts,” “potential,” “would,” “will likely result,” “continue,” and similar expressions (including the negative versions of such words or expressions).

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Cipher and its management, are inherently uncertain. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: volatility in the price of Cipher’s securities due to a variety of factors, including changes in the competitive and regulated industry in which Cipher operates, Cipher’s evolving business model and strategy and efforts it may make to modify aspects of its business model or engage in various strategic initiatives, variations in performance across competitors, changes in laws and regulations affecting Cipher’s business, the ability of Cipher’s customers, tenants, and other counterparties to perform their contractual obligations, the ability to Cipher to complete its data centers and future strategic growth initiatives in a timely manner or within anticipated cost estimates, risks relating to the development, construction, and operation of Cipher’s data centers, the availability of capital and financing on acceptable terms, changes in market demand, and the ability to implement business plans, forecasts, and other expectations and to identify and realize additional opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Cipher’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, Cipher’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the SEC on August 4, 2026, and in Cipher’s subsequent filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Cipher assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Website Disclosure

The Company maintains a dedicated investor website at https://investors.cipherdigital.com/ (“Investors’ Website”). Financial and other important information regarding the Company is routinely posted on and accessible through the Investors’ Website. Cipher uses its Investors’ Website as a distribution channel of material information about the Company, including through press releases, investor presentations, reports and notices of upcoming events. Cipher intends to utilize its Investors’ Website as a channel of distribution to reach public investors and as a means of disclosing material non-public information for complying with disclosure obligations under Regulation FD. In addition, you may sign up to automatically receive email alerts and other information about the Company by visiting the “Email Alerts” option under the Investor Resources section of Cipher’s Investors’ Website and submitting your email address.

Contacts:

Investor Contact:
Courtney Knight
Head of Investor Relations at Cipher Digital
courtney.knight@cipherdigital.com

Media Contact:
Ryan Dicovitsky
Dukas Linden Public Relations
CipherDigital@DLPR.com

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS^® System to Firefly’s nationwide network of Evoke™ clinicians –

– Collaboration brings together an FDA-cleared pediatric ADHD treatment and Firefly’s objective brain-function assessment platform and AI-driven ADHD biomarker research –

– Monarch offers an at-home, non-medication treatment option for eligible children ages 7 through 12 ––

KENMORE, N.Y. and LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an artificial intelligence (“AI”) company advancing precision neuroscience, and NeuroSigma, Inc. (“NeuroSigma”), a bioelectronic medical device company, today announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS^® System through Firefly’s growing nationwide network of Evoke™ clinician customers.

The Monarch eTNS^® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder (“ADHD”) cleared by the U.S. Food and Drug Administration (“FDA”). Under the partnership, Firefly will introduce the Monarch device to psychiatry, neurology and behavioral health practices that use its FDA 510(k)-cleared, AI-powered Evoke™ EEG/ERP platform.

The collaboration brings together complementary technologies designed to address two significant needs in pediatric ADHD care: access to objective information about brain function and availability of a non-medication treatment option for eligible patients.

According to a 2024 study published in the Journal of Clinical Child & Adolescent Psychology, approximately one in nine U.S. children has received an ADHD diagnosis, representing an estimated 7.1 million children. And among the approximately 6.5 million children with current ADHD, nearly one-third received no ADHD-specific treatment.¹ At the same time, many families are seeking alternatives to stimulant medication for their children.²^, ³

“This partnership represents an important step toward a more objective and personalized approach to pediatric ADHD care,” said Greg Lipschitz, Chief Executive Officer of Firefly. “Clinicians need better tools to understand how an individual patient’s brain is functioning, more treatment options from which to choose and objective ways to evaluate changes over time. By introducing NeuroSigma’s FDA-cleared, non-drug therapy to our Evoke clinician network, we are connecting measurement-driven practices with an important treatment option for eligible children and their families.”

Firefly’s Evoke™ platform combines quantitative electroencephalography (“qEEG”) and event-related potential (“ERP”) testing with AI-powered analytics. Drawing upon Firefly’s proprietary database of more than 200,000 EEG/ERP brain scans, Evoke™ provides clinicians with objective information about individual brain function, including in patients whose symptoms may overlap across multiple conditions, and enables clinicians to track changes over time.

In March 2026, Firefly announced the discovery of EEG/ERP biomarkers, identified using data collected through Evoke™, that may help differentiate among the three ADHD presentations: predominantly inattentive, predominantly hyperactive-impulsive and combined. Subject to further research and validation, Firefly believes these findings could ultimately help clinicians better match patients with appropriate treatment approaches and objectively monitor their response to intervention.

The prescription-only Monarch eTNS^® System is a palm-sized device that delivers mild external trigeminal nerve stimulation (eTNS) through a small adhesive patch placed on a child’s forehead while the child sleeps. It is FDA-cleared as a monotherapy for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD medication.

NeuroSigma commenced U.S. sales of its second-generation Monarch device in July 2026, following the development of a waitlist comprising more than 1,500 patients, caregivers and healthcare providers. In September, the company expanded payment options for families, including third-party installment plans.

“For too long, we have relied on symptom checklists and traditional evaluations alone to understand a child’s brain,” said Lauren Hernandez, M.D., a board-certified pediatrician with advanced certification in genomic medicine, and Chief Medical Officer of the pediatric program for NuWell Medicine. “Advanced qEEG technology, such as Evoke™, allows us to see how a child’s brain is actually functioning in real time, giving us a deeper understanding of attention, learning, emotional regulation, and overall neurological health. This technology helps identify the unique patterns behind challenges often labeled as ADHD, while also revealing when symptoms may be driven by anxiety, sensory processing differences, autonomic nervous system dysregulation, or other underlying factors. By understanding how the brain, gut, and autonomic nervous system work together, we can create more personalized and effective roadmaps that support resilience, health, and lifelong success. Evoke™ provides valuable insights that can help validate the need for medication when appropriate, while also helping families avoid unnecessary treatment when the root cause lies elsewhere. We are also excited about emerging tools, such as the Monarch eTNS^® System, which offer new opportunities to support children with ADHD and autism. For the first time, we have objective tools to measure progress and improvement over time, aligning perfectly with the Reformative Medicine approach of identifying what’s off balance, optimizing function, and restoring balance across the body’s interconnected systems.”

Under the agreement, Firefly will introduce the Monarch eTNS^® System to its Evoke™ clinician customers and support clinician education regarding the therapy. NeuroSigma will provide clinical training, prescribing support and product fulfillment through its specialty pharmacy partner.

“Firefly has built a network of clinicians who are already embracing a more objective, measurement-driven approach to brain health,” said Colin Kealey, M.D., President and Chief Executive Officer of NeuroSigma. “These clinics are well positioned to evaluate innovative treatment options for children and families seeking an alternative to medication. With our second-generation Monarch device now shipping and expanded payment options available, this partnership gives us an efficient pathway to educate more clinicians and broaden access to the first FDA-cleared, non-drug treatment for pediatric ADHD.”

Sources

¹ Danielson ML, Claussen AH, Bitsko RH, Katz SM, Newsome K, Blumberg SJ, Kogan MD, Ghandour R. ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment. J Clin Child Adolesc Psychol. 2024 May-Jun;53(3):343-360. doi: 10.1080/15374416.2024.2335625. Epub 2024 May 22. PMID: 38778436; PMCID: PMC11334226.

² Lu SV, Leung BMY, Bruton AM, Millington E, Alexander E, Camden K, Hatsu I, Johnstone JM, Arnold LE. Parents’ priorities and preferences for treatment of children with ADHD: Qualitative inquiry in the MADDY study. Child Care Health Dev. 2022 Sep;48(5):852-861. doi: 10.1111/cch.12995. Epub 2022 Mar 25. PMID: 35244227; PMCID: PMC10215012.

³ Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020 Oct;51(5):315-335. doi: 10.1055/s-0040-1701658. Epub 2020 Jun 19. PMID: 32559806; PMCID: PMC7508636.

About NeuroSigma

NeuroSigma is a bioelectronic medical device company based in Los Angeles, California. Its lead product, the Monarch eTNS^® System, is the first non-drug treatment for pediatric ADHD cleared by the FDA. NeuroSigma is also investigating the Monarch eTNS^® System in additional neurodevelopmental and neurological indications, including autism spectrum disorder, learning disabilities and drug-resistant epilepsy, for which the FDA has granted Breakthrough Device Designation; these pipeline indications are investigational and not FDA-cleared.

For more information, visit www.neurosigma.com and www.monarch-etns.com.

About Firefly Neuroscience

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient’s brain is functioning. Firefly’s proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared Evoke™ System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.

Please visit www.fireflyneuro.com for more information.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly, including statements regarding the anticipated benefits, scope, and results of the collaboration between Firefly and NeruSigma, statements regarding NeruSigma’s business, business, product and commercial plans; Firefly’s ADHD biomarker research and product development; and statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Important Safety Information

The Monarch eTNS^® System is available by prescription only. It is indicated for the treatment of pediatric ADHD as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medication and is intended for home use during sleep under the supervision of a caregiver. Monarch should not be used by patients with an implanted cardiac or neurostimulation system or an implanted metallic or electronic device in the head. Do not apply the device to the neck or chest, do not use it in the bath or shower, and do not use it in the presence of electrical monitoring equipment such as cardiac monitors. Apply the patch only to healthy, clean, intact skin. The most commonly reported side effects are drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue. Talk with your child’s clinician about whether Monarch is right for your child.

For complete safety information, see the Instructions for Use.

Investor & Media Contacts

For Firefly
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com

For NeuroSigma
Colin Kealey, M.D.
President and Chief Executive Officer
ckealey@neurosigma.com

Martin Bech Holte, primary insider and board member of SalMar ASA, has on 25 September 2026 acquired 2,000 shares in SalMar ASA at a price of NOK 565 per share. After the transaction, Martin Bech Holte owns 3,200 shares in SalMar.

Please see attached notification form in accordance with the Market Abuse Regulation article 19.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and the Market Abuse Regulation Article 19.

Attachment

• PDMR form – Martin Bech Holte

To Nasdaq Copenhagen A/S	25 September 2026
	Announcement no. 82/2026

Fixing of Coupon Interest Rate

Interest rate for Jyske Realkredit’s:

Series BRF454BOA 38 with ISIN DK0009361628 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154B 38 with ISIN DK0009361701 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154E 41 with ISIN DK0009366932 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series BRF454EOA 41 with ISIN DK0009367070 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series 422.E.OA Cb3.ju27 RF with ISIN DK0009412207 has per 1 October 2026 and until and including 1 January 2027 been set at 2.91 % p.a.

Series G-422.E.OA Cb3.ju27 RF with ISIN DK0009412397 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series 422.B.OA Cb3.ju27 RF with ISIN DK0009412470 has per 1 October 2026 and until and including 1 January 2027 been set at 3.00 % p.a.

Series G422.E.OA Cb3.ju27 RF with ISIN DK0009414682 has per 1 October 2026 and until and including 1 January 2027 been set at 2.76 % p.a.

Series 422.E.OA Cb3.ju28 RF with ISIN DK0009414765 has per 1 October 2026 and until and including 1 January 2027 been set at 2.79 % p.a.

Series 422.E.OA Cb3.ju29 RF with ISIN DK0009417198 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series G422.E.OA Cb3 ju29 RF with ISIN DK0009417271 has per 1 October 2026 and until and including 1 January 2027 been set at 2.85 % p.a.

Series 422.E.OA Cb3.ju30 RF with ISIN DK0009419137 has per 1 October 2026 and until and including 1 January 2027 been set at 2.62 % p.a.

Series SNP322.ap.28 with ISIN DK0009417008 has per 1 October 2026 and until and including 1 January 2027 been set at 3.23 % p.a.

Questions may be addressed to Christian Bech-Ravn, tel. (+45) 89 89 92 25.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

25 September 2026

LSE Code: 3EUS

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY
(a public company incorporated with limited liability in Ireland)
WISDOMTREE EURO STOXX 50® 3X DAILY SHORT SECURITIES
ISIN: XS3306517502

RESULTS OF MEETING OF THE ETP SECURITYHOLDERS

WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”) wishes to announce that the Extraordinary Resolution regarding the reduction in the principal amount of the WisdomTree EURO STOXX 50® 3x Daily Short Securities (the “Affected Securities”) from EUR 2.8 to EUR 0.28, as set out in a notice to holders of the Affected Securities dated 4 August 2026, was passed at an adjourned meeting of the holders of the Affected Securities held at 11am on 25 September 2026.

As a result, the Deed of Amendment has been duly executed by the Issuer, the Manager and the Trustee to put the proposed amendments to the Trust Deed into effect from 25 September 2026.

Company Concentrates Its System-of-Systems Thesis on Three Pillars: The Quantum Antenna, One-Way Attack / Interceptor Drones, and the MAHCA Operating System — Anchored at Its Bridgeport, Connecticut Manufacturing Facility as Quantum Cyber Advances Toward Commercialization

Norwalk, CT, Sept. 25, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced a sharpened strategic focus, reframing the Company’s thesis for the era of GPS-deficient, autonomous warfare, and presented its updated Corporate Investor Presentation. The full presentation is available at https://quantum-cyber.ai/investors/presentations.

The presentation consolidates the Company’s refocused strategy, technology portfolio, and manufacturing footprint into a single investor-facing document. Key sections include:

Warfare, Reimagined for the Quantum Era. Quantum Cyber’s strategy is now organized around a single thesis: the next war will be fought in environments where GPS fails, where electronic warfare dominates, and where mass-produced attritable autonomy decides the outcome. The Company’s exclusively-licensed quantum antenna technology, executed with Project LightShift, Inc. on June 11, 2026, is positioned as the differentiating layer of the platform — an unjammable, magnetic-field-based navigation, communications and energy-capture reference for autonomous systems operating in contested environments where satellite-guided precision has become a single point of failure.

Concentration on Three Product Pillars. Quantum Cyber has narrowed its System-of-Systems platform focus to three product pillars: one-way attack drones and interceptors; the quantum antenna, invented by Dr. Wolf Kohn, providing power, communications and navigation in a single component; and the MAHCA operating system, the Multiple Agent Hybrid Control Architecture that orchestrates coordinated swarm behavior across autonomous platforms. Maritime programs and other exploratory initiatives have been de-emphasized so the Company can concentrate capital, engineering, and commercial resources on near-term commercialization.

Total Addressable Market — Four Target Applications. Quantum Cyber’s commercial strategy is now focused on Border Patrol, Warfare / Defense UAS, Law Enforcement, and the GPS-Alternative / Quantum Navigation category, the latter validated by parallel programs at Honeywell and Northrop Grumman.

Ukraine Doctrine and the $5,000 Drone. The Company’s platforms are engineered for the attritable-autonomy economics validated in the Ukraine conflict, where $5,000-class drones have neutralized multi-million-dollar armored platforms in electronic-warfare-saturated environments within 20 km of the front line.

Leadership Depth. Dr. Wolf Kohn, Chief Scientist and Head of Quantum — inventor of the licensed quantum antenna technology; former Engineer of the Year at Lockheed Martin, Boeing and NASA; prior work with DARPA; and a former MIT professor and graduate. Tzvi Lev, Head of Middle East Sales — a high-ranking reserves officer leading the Company’s Middle East and Gulf commercial channel. Dennis Schnur, Head of U.S. Sales — a U.S. Army veteran (77th ARCOM) with 60+ years leading large-scale U.S. distribution operations, anchoring the Company’s U.S. commercial build-out. The Company’s Ukrainian engineering team continues to lead product development, contributing five years of active-electronic-warfare combat experience.

Made in America — Vertically Integrated. Quantum Cyber’s manufacturing strategy is anchored at its owned ~50,000 sq ft facility in Bridgeport, Connecticut, acquired July 16, 2026. An 80-unit 3D printing drone production farm was installed and became operational on August 31, 2026. Ongoing equipment procurement includes motors, CNC machinery for airframes, routers and propellers, and injection-molding capacity, supported by a High-Density MIL-STD Power Architecture designed for low-cost, scalable drone assembly. Targeted annual production capacity of 100,000 drones represents forward-looking management projections and is not current operational capacity.

Policy Tailwinds. Executive Order 14307 establishes American drone dominance as an explicit national security and industrial priority, and the current administration’s Buy American procurement mandate and tariff regime carry a structural, tariff-advantaged position for U.S.-based defense manufacturers such as Quantum Cyber. The Trump Administration is seeking approximately $55 billion for drone and autonomous warfare programs in the fiscal year 2027 defense budget.

“The next war will be fought in GPS-denied environments by autonomous systems at scale, and we have concentrated our platform, our team, and our manufacturing footprint around that reality,” said David Lazar, Chief Executive Officer of Quantum Cyber. “Quantum navigation, interceptors, MAHCA, and a U.S. factory — that is the strategy, and every dollar of capital and every hire from here forward is measured against it.”

About Quantum Cyber N.V.
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops combat-proven autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea. For more information, visit www.quantum-cyber.ai.

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements relate to, among other things, management’s strategic focus; the anticipated development, integration, and commercialization of the Company’s quantum antenna, interceptor, one-way attack, and MAHCA operating system technologies; the exclusive Intellectual Property License Agreement with Project LightShift, Inc. dated June 11, 2026; targeted total addressable markets and target applications; targeted annual production capacity of 100,000 drones and other manufacturing plans and equipment procurement at the Bridgeport, Connecticut facility; tariff, policy, and budget tailwinds, including the Fiscal Year 2027 defense budget request; and the Company’s broader business strategy and technology pipeline. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet development, prototype, or manufacturing milestones; (ii) the failure of Project LightShift, Inc. to perform its obligations under the License Agreement; (iii) changes in applicable laws, regulations, or trade and procurement policy; (iv) an inability to successfully pursue new initiatives; and (v) other risks and uncertainties discussed from time to time in other reports and public filings with the Securities and Exchange Commission (the “SEC”) by the Company. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com